Skip to main content

Table 2 The distribution of outcomes in the comparison cohorts

From: Cardiovascular risks and bleeding with non-vitamin K antagonist oral anticoagulant versus warfarin in patients with type 2 diabetes: a tapered matching cohort study

 

Unmatched cohorts

Cohorts after coarsened exact matching

Incident NOAC users (N = 862)

Incident warfarin users (N = 626)

Incident NOAC users (N = 582)

Incident warfarin users (N = 486)

Hospitalisation mainly due to CVD, n (%)

190 (22.0)

63 (10.1)

91 (17.2)

44 (9.1)

Hospitalisation mainly due to bleeding, n (%)

50 (5.8)

33 (5.3)

25 (4.7)

18 (3.7)

Re-hospitalisation mainly due to CVD, n (%)

70 (8.1)

15 (2.4)

37 (7.0)

8 (1.7)

  1. CVD indicates cardiovascular diseases